Dr. Pomerantz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
711 Harvest Hill Dr
Chalfont, PA 18914Phone+1 609-730-7524- Is this information wrong?
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1989 - 1990- Massachusetts General HospitalResidency, Internal Medicine, 1982 - 1988
Johns Hopkins University School of MedicineClass of 1982
Certifications & Licensure
PA State Medical License 1990 - 2024
MA State Medical License 1985 - 2019- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 44 citationsA Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative ColitisMatthew R. Henn, Edward J. O’Brien, Liyang Diao, Brian G. Feagan, William J. Sandborn, Curtis Huttenhower, Jennifer R. Wortman, Barbara H. McGovern, Sherry Wang-Weigan...> ;Gastroenterology. 2021 Jan 1
- 61 citationsExebacase for patients with Staphylococcus aureus bloodstream infection and endocarditisVance G. Fowler, Anita Das, Joy Lipka-Diamond, Raymond Schuch, Roger J. Pomerantz, Luis Jauregui-Peredo, Adam Bressler, David C. Evans, Gregory J. Moran, Mark E. Rupp,...> ;The Journal of Clinical Investigation. 2020 Jul 1
- 90 citationsSER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.Barbara H. McGovern, Christopher B. Ford, Matthew R. Henn, Darrell S. Pardi, Sahil Khanna, Elizabeth L. Hohmann, Edward J. O’Brien, Christopher A. Desjardins, Patricia...> ;Clinical Infectious Diseases. 2021 Jun 15
- Join now to see all
Press Mentions
ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 15th, 2023- ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeApril 26th, 2023
- ContraFect Begins Phase Ib/II Clinical Trial of ExebacaseApril 4th, 2023
- Join now to see all
Grant Support
- Astrocytic HIV Reservoirs: Molecular MechanismsNational Institute Of Neurological Disorders And Stroke2008–2009
- Astrocytic HIV Reservoirs: Molecular MechanismsNational Institute Of Neurological Disorders And Stroke2005–2007
- HIV/AIDS Intravirion Reverse Transcription And VirucidesNational Institute Of Allergy And Infectious Diseases2004
- Alcohol'S Effects On HIV-1 And The Blood: Brain BarrierNational Institute On Alcohol Abuse And Alcoholism2002–2004
- Gene Therapy Of AIDS DementiaNational Institute Of Neurological Disorders And Stroke2002–2004
- Effects Of HIV -1 Proteins On The Blood/ Brain BarrierNational Institute Of Neurological Disorders And Stroke2000–2004
- Retroviral Vectors For Gene Therapy Of HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2002–2003
- Anti HIV Molecular Therapeutics Targeting Chemokine ReceptorsNational Institute Of Neurological Disorders And Stroke2000–2002
- Molecular Mechanisms Of HIV1 Transmission During HaartNational Institute Of Allergy And Infectious Diseases1999–2002
- Molecular Therapeutics For HIV1 Induced CNS DysfunctionNational Institute Of Mental Health1998–2002
- HIV1 REV And Nucleocytoplasmic Trafficking Of ProteinsNational Institute Of Allergy And Infectious Diseases1999–2001
- Intravirion Reverse Transcription And HIV-1 PathogenesisNational Institute Of Allergy And Infectious Diseases1996–1999
- HIV-1 Replication In Astrocyte Glial CellsNational Institute Of Neurological Disorders And Stroke1996–1998
- Core--Molecular VirologyNational Institute Of Neurological Disorders And Stroke1996–1998
- HIV-1 Replication In Astrocyte Glial CellsNational Institute Of Neurological Disorders And Stroke1996–1997
- Intracellular Antibodies And HIV 1National Institute Of Allergy And Infectious Diseases1994–1997
- HIV-1 Transmission In VivoNational Institute Of Allergy And Infectious Diseases1994–1997
- Cellular Control Of HIV 1 Latency And ReplicationNational Institute Of Allergy And Infectious Diseases1994
- Cellular Control Of HIV-1 Latency And ReplicationNational Institute Of Allergy And Infectious Diseases1992–1993
- Cellular Tropism Of HIVNational Institute Of Allergy And Infectious Diseases1990–1992
- Cellular Tropism Of HIVNational Institute Of Allergy And Infectious Diseases1989–1990
- HIV Neutralizing Antibodies In AIDSNational Institute Of Allergy And Infectious Diseases1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
